Pfizer Inc. (NYSE:PFE) Shares Purchased by Everett Harris & Co. CA

Everett Harris & Co. CA boosted its position in Pfizer Inc. (NYSE:PFE) by 21.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 218,344 shares of the biopharmaceutical company’s stock after acquiring an additional 38,870 shares during the quarter. Everett Harris & Co. CA’s holdings in Pfizer were worth $6,319,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Key Client Fiduciary Advisors LLC raised its holdings in Pfizer by 16.9% during the third quarter. Key Client Fiduciary Advisors LLC now owns 28,710 shares of the biopharmaceutical company’s stock worth $831,000 after purchasing an additional 4,156 shares in the last quarter. Bonness Enterprises Inc. raised its holdings in Pfizer by 3.7% during the third quarter. Bonness Enterprises Inc. now owns 156,208 shares of the biopharmaceutical company’s stock worth $4,521,000 after purchasing an additional 5,600 shares in the last quarter. TriaGen Wealth Management LLC acquired a new stake in Pfizer during the third quarter worth approximately $202,000. Commonwealth Equity Services LLC raised its holdings in Pfizer by 0.4% during the third quarter. Commonwealth Equity Services LLC now owns 4,693,123 shares of the biopharmaceutical company’s stock worth $135,819,000 after purchasing an additional 18,198 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in Pfizer by 6.1% during the third quarter. Blue Trust Inc. now owns 53,559 shares of the biopharmaceutical company’s stock worth $1,499,000 after purchasing an additional 3,102 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday. They set a “market perform” rating and a $32.00 price objective on the stock. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.05 during trading on Friday, hitting $29.22. 24,244,872 shares of the company were exchanged, compared to its average volume of 37,106,250. The company has a market cap of $165.58 billion, a price-to-earnings ratio of -487.17, a PEG ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The firm’s fifty day moving average price is $29.07 and its 200 day moving average price is $28.44.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.